Don't Wait to Anticoagulate
‘Don’t Wait to Anticoagulate’ is an initiative led by the West of England Academic Health Science Network. It is a joint working project with Bayer and has included participation from Boehringer-Ingelheim, Pfizer and Daiichi-Sankyo (all of which has been in compliance with the ABPI Code of Conduct.
The project has the following aims:
- To support primary care to reduce the burden of Atrial Fibrillation(AF)-related Stroke in our population through achieving the following clinical aims:
- To increase rates of appropriate anticoagulation use in AF patients identified as high risk of AF-related stroke.
- Optimise anticoagulation of AF patients unstable on Warfarin through transfer to Direct Oral Anticoagulants in accordance with NICE Guidance (CG 180)
- To develop a quality improvement approach that will enable clinicians to re-evaluate how identification, diagnosis and treatment occurs and consider NOACs alongside traditional anticoagulants
- To develop a strategic approach that will enable a CCG to sustainably drive implementation of the above (including appreciation of financial and other benefits and risks of implementation).
The project does this by achieving the following objectives:
- Reduction in the number of high-risk patients currently receiving no treatment;
- Reduction in the number of high-risk patients currently receiving anti-platelet therapy;
- Improvement in the efficacy of anticoagulation in patients unstable on Warfarin through the offer of NOACs in line with local formularies.
- Increase the number of GP practices with the knowledge of quality improvement approaches to support the embedding of best practice.
- Increase in clinician confidence in prescribing and managing all OACs